{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:08:58Z","timestamp":1780722538433,"version":"3.54.1"},"reference-count":23,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:p>Systemic juvenile idiopathic arthritis (sJIA) is an aggressive form of childhood arthritis accompanied by persistent systemic inflammation. Patients with sJIA often exhibit poor response to conventional disease-modifying antirheumatic drugs, and chronic glucocorticoid use is associated with significant adverse effects. Although biologics used to target interleukin 1 and interleukin 6 are efficacious, the long-term commitment to frequent injections or infusions remains a challenge in young children. Janus-activated kinase (JAK) inhibitors block the signaling of numerous proinflammatory cytokines and are now used clinically for the treatment of rheumatoid arthritis in adults. Whether this new class of medication is effective for sJIA has not been reported. Here, we describe the case of a 13-year-old girl with recalcitrant sJIA characterized by polyarticular arthritis, fever, lymphadenopathy, and serological features of inflammation. She showed minimal response to nonsteroidal antiinflammatory drugs, glucocorticoids, conventional disease-modifying antirheumatic drugs, and etanercept. She also developed osteoporosis and vertebral compression fracture as the result of chronic glucocorticoid therapy. Oral therapy with the JAK inhibitor tofacitinib was initiated, and the patient experienced steady improvement of both arthritis and systemic features. Complete remission was achieved after 3 months, and no evidence of disease activity or adverse effects was seen through 6 months of follow-up. Our experience reveals the effectiveness of JAK inhibition in a case of refractory sJIA. Tofacitinib is an intriguing oral alternative to the available biologics for children with sJIA, and its efficacy and safety should be further assessed by clinical trial.<\/jats:p>","DOI":"10.1542\/peds.2018-2845","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T12:29:12Z","timestamp":1554380952000},"source":"Crossref","is-referenced-by-count":51,"title":["Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.1542","volume":"143","author":[{"given":"Zhixiang","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoling","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"issue":"2","key":"2021121013183192600_B1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review.","volume":"81","author":"Thierry","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2021121013183192600_B2","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.","volume":"25","author":"Petty","year":"1998","journal-title":"J Rheumatol"},{"issue":"4","key":"2021121013183192600_B3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","article-title":"Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies.","volume":"31","author":"Pardeo","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"2021121013183192600_B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1442-200X.1997.tb03593.x","article-title":"Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan.","volume":"39","author":"Fujikawa","year":"1997","journal-title":"Acta Paediatr Jpn"},{"issue":"1\u20132","key":"2021121013183192600_B5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/pr.2013.187","article-title":"Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.","volume":"75","author":"Correll","year":"2014","journal-title":"Pediatr Res"},{"issue":"1","key":"2021121013183192600_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/14397595.2014.902747","article-title":"Pathogenesis of systemic inflammatory diseases in childhood: \u201clessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome\u201d.","volume":"25","author":"Yokota","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2021121013183192600_B7","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2021121013183192600_B8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"2021121013183192600_B9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis.","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"52","key":"2021121013183192600_B10","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1073\/pnas.1520779112","article-title":"HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.","volume":"112","author":"Ombrello","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"2021121013183192600_B11","doi-asserted-by":"crossref","first-page":"15785","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis.","volume":"112","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2021121013183192600_B12","first-page":"1670","article-title":"Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis.","volume":"28","author":"Pignatti","year":"2001","journal-title":"J Rheumatol"},{"issue":"9","key":"2021121013183192600_B13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"issue":"6","key":"2021121013183192600_B14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2021121013183192600_B15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"25","key":"2021121013183192600_B16","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2021121013183192600_B17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"2021121013183192600_B18","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2021121013183192600_B19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/RHU.0000000000000456","article-title":"Tofacitinib response in juvenile idiopathic arthritis (JIA) and collagenous colitis.","volume":"22","author":"Tseng","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"2021121013183192600_B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/TCRM.S138677","article-title":"European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.","volume":"14","author":"Kawalec","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"2021121013183192600_B21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121013183192600_B22","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2021121013183192600_B23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease [published correction appears in Nat Rev Rheumatol. 2017;13(5):320].","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2845\/1076914\/peds_20182845.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2845\/1076914\/peds_20182845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T02:23:39Z","timestamp":1639189419000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/143\/5\/e20182845\/37164\/Tofacitinib-Treatment-of-Refractory-Systemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-2845","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"article-number":"e20182845"}}